score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable			Clinical evidence	Copy Number	PAK1	Amplification				0.0	0.0																Putatively Actionable	0.0	PAK1 amplification showed reduced recurrence-free survival and decreased benefit from Tamoxifen in a randomized control trial of postmenopausal breast cancer patients.	"Bostner, Josefine, et al. ""Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer."" Oncogene 26.49 (2007): 6997-7005."	https://doi.org/10.1038/sj.onc.1210506	0				PAK1 Amplification		MEL-IPI_Pat115	MEL-IPI_Pat115-Tumor-SM-5X2QS	
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.D892N	0.16	50.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137						0	0.0	0.0	0.0	RET p.D892N (Missense)		MEL-IPI_Pat115	MEL-IPI_Pat115-Tumor-SM-5X2QS	MEL-IPI_Pat115-Normal-SM-5X2RA
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat115		
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.F876L	0.3496	123.0	0.0	0.0																Investigate Actionability	0.0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060	0	5.0	0.6	0.0587	BLM p.F876L (Missense)		MEL-IPI_Pat115	MEL-IPI_Pat115-Tumor-SM-5X2QS	MEL-IPI_Pat115-Normal-SM-5X2RA
Biologically Relevant				Rearrangement	ERBB3	Fusion	ERBB3--SLC27A2			0.0	0.0																					0				ERBB3--SLC27A2 Fusion		MEL-IPI_Pat115		
Biologically Relevant				Rearrangement	AKT1	Fusion	AKT1--ZNF850			0.0	0.0																					0				AKT1--ZNF850 Fusion		MEL-IPI_Pat115		
Biologically Relevant				Rearrangement	ERBB3	Fusion	TMEM2--ERBB3			0.0	0.0																					0				TMEM2--ERBB3 Fusion		MEL-IPI_Pat115		
Biologically Relevant				Rearrangement	PRPF8	Fusion	RP11-705C15.3--PRPF8			0.0	0.0																					0				RP11-705C15.3--PRPF8 Fusion		MEL-IPI_Pat115		
Biologically Relevant				Copy Number	POLE	Deletion				0.0	0.0																					0				POLE Deletion		MEL-IPI_Pat115	MEL-IPI_Pat115-Tumor-SM-5X2QS	
Biologically Relevant				Copy Number	CHEK1	Deletion				0.0	0.0																					0				CHEK1 Deletion		MEL-IPI_Pat115	MEL-IPI_Pat115-Tumor-SM-5X2QS	
Biologically Relevant				Copy Number	FLI1	Deletion				0.0	0.0																					0				FLI1 Deletion		MEL-IPI_Pat115	MEL-IPI_Pat115-Tumor-SM-5X2QS	
Biologically Relevant				Microsatellite Stability	Supporting variants		POLE Deletion, PRDM2 p.278_278E>EE (Insertion), PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: POLE Deletion, PRDM2 p.278_278E>EE (Insertion), PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		MEL-IPI_Pat115		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.324																									0				COSMIC Signature (version 2) 1 (32%)		MEL-IPI_Pat115		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.276																									0				COSMIC Signature (version 2) 7 (28%)		MEL-IPI_Pat115		
